These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36341032)

  • 1. In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilin.
    Taylor RM; Karlowsky JA; Baxter MR; Adam HJ; Walkty A; Lagacé-Wiens P; Zhanel GG
    J Assoc Med Microbiol Infect Dis Can; 2021 Jun; 6(2):149-162. PubMed ID: 36341032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms.
    Paukner S; Mendes RE; Arends SJR; Gassner G; Gelone SP; Sader HS
    J Antimicrob Chemother; 2024 Feb; 79(2):360-369. PubMed ID: 38113528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin.
    Eraikhuemen N; Julien D; Kelly A; Lindsay T; Lazaridis D
    Infect Dis Ther; 2021 Mar; 10(1):149-163. PubMed ID: 33528794
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Wu S; Zheng Y; Guo Y; Yin D; Zhu D; Hu F
    Front Microbiol; 2020; 11():578824. PubMed ID: 33042095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA; Farrell DJ; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
    Farrell DJ; Flamm RK; Jones RN; Sader HS
    Diagn Microbiol Infect Dis; 2013 Jan; 75(1):86-8. PubMed ID: 23146404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).
    Paukner S; Gelone SP; Arends SJR; Flamm RK; Sader HS
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.
    Karlowsky JA; Adam HJ; Decorby MR; Lagacé-Wiens PR; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2837-46. PubMed ID: 21402844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
    Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
    Veve MP; Wagner JL
    Pharmacotherapy; 2018 Sep; 38(9):935-946. PubMed ID: 30019769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
    Karlowsky JA; Adam HJ; Baxter MR; Lagacé-Wiens PR; Walkty AJ; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5600-11. PubMed ID: 23979759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in the Middle East and Africa: AWARE global surveillance programme 2015-2018.
    Karlowsky JA; Hackel MA; Bouchillon SLK; Lowman W; Kotb REM; Mohamed N; Stone GG; Sahm DF
    J Glob Antimicrob Resist; 2021 Mar; 24():249-256. PubMed ID: 33373731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.
    Paukner S; Sader HS; Ivezic-Schoenfeld Z; Jones RN
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4489-95. PubMed ID: 23836172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from the Survey of Antibiotic Resistance (SOAR) 2016-17 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Bratus E; Yuvko O; Pertseva T; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i100-i111. PubMed ID: 32337596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
    Morrissey I; Robbins M; Viljoen L; Brown DF
    J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Anwar S; Nizamuddin S; Malik N; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i76-i87. PubMed ID: 32337594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
    Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H
    Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program.
    Gordon KA; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2003 Aug; 46(4):285-9. PubMed ID: 12944021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.